Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

China's CAS COVID-19 vaccine induces immune response in mid-stage tests

12/23/2020 | 02:16am EDT

BEIJING, Dec 23 (Reuters) - A coronavirus vaccine candidate developed by the Chinese Academy of Sciences (CAS) was found to be safe and triggered immune responses in early and mid-stage trials, researchers said on Tuesday.

A late-stage trial of the ZF2001 vaccine, which CAS is developing with a unit of Chongqing Zhifei Biological Products , began last month in China. It aims to recruit 29,000 people across China, Uzbekistan, Indonesia, Pakistan and Ecuador.

The candidate did not cause serious adverse events, with common mild side-effects including injection pain, redness and swelling, researchers at the Chongqing Zhifei unit, CAS, and other Chinese institutes said in a paper published on Tuesday ahead of peer review. https://bit.ly/3nKZzt0

The combined data from Phase 1 and 2 trials involved 950 healthy Chinese participants aged 18-59. Low dose and high dose versions were tested, and the Phase 2 study also tested two doses versus three doses for both the low dose and high dose versions.

The higher dose given via three injections spaced 30 days apart did not induce an improved immune reponse compared to the lower dose, the paper said. The Phase 3 trial will look at the lower dose version given over three injections, it said.

Neutralising antibodies against the virus were detected among at least 93% participants who received three shots in different groups. The levels of vaccine-triggered antibodies were higher than those seen in samples of patients recovered from the disease, researchers said.

However, these antibody-based readings are on their own not sufficient to predict how effective ZF2001 will be in protecting people from the virus, researchers said, warning they could not yet determine the duration of immune responses.

The vaccine also triggered moderate cell-based immune responses, a crucial part of the human immune system that works differently from antibodies.

ZF2001 is a protein subunit vaccine, which uses a harmless piece of the SARS-CoV-2 virus rather than the entire germ.

Four other Chinese vaccines from Sinopharm, Sinovac Biotech and CanSino Biologics have also entered Phase 3 clinical trials.

(Reporting by Roxanne Liu and Ryan Woo; Editing by Edwina Gibbs)

ę Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
CANSINO BIOLOGICS INC. -6.96% 270.2 End-of-day quote.53.09%
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. -8.71% 156.2 End-of-day quote.5.60%
SINOPHARM GROUP CO., LTD. -1.36% 21.7 End-of-day quote.15.06%
SINOVAC BIOTECH LTD. -0.31% 6.47 Delayed Quote.0.00%
11:33aSINOVAC BIOTECH : Brazil says China's Sinopharm seeks COVID-19 vaccine emergency..
10:25aSINOVAC BIOTECH : Antibodies from Sinovac's COVID-19 shot fade after about 6 mon..
07/24SINOVAC BIOTECH : Indonesia prepares more ICU units, waits to see if COVID curbs..
07/23SINOVAC BIOTECH : China's Sinovac evaluates vaccine plant in Chile
07/20SINOVAC BIOTECH : Receives Approval on Sabin Strain Based Inactivated Polio Vacc..
07/20SINOVAC BIOTECH : CoronaVac Used on Child Population in China, Good Antibody Lev..
07/20SINOVAC Biotech Ltd. Announces Use of CoronaVac, its COVID-19 Vaccine on Chil..
07/19SINOVAC BIOTECH : Polio Vaccine Gets China's Medical Regulator OK
07/19SINOVAC BIOTECH : Receives Approval on Sabin Strain Based Inactivated Polio Vacc..
07/19SINOVAC Receives Approval on Sabin Strain Based Inactivated Polio Vaccine to ..
More news
Financials (USD)
Sales 2020 511 M - -
Net income 2020 110 M - -
Net cash 2020 1 040 M - -
P/E ratio 2020 6,66x
Yield 2020 -
Capitalization 642 M 642 M -
EV / Sales 2019 1,86x
EV / Sales 2020 -0,78x
Nbr of Employees 1 959
Free-Float 33,1%
Duration : Period :
Sinovac Biotech Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Wei Dong Yin Chairman, President, CEO, Secretary & MD
Nan Wang CFO & Vice President-Business Development
Qiang Gao Chief Operating Officer & Vice President
Yuk Lam Lo Independent Director
Jian Li Independent Director
Sector and Competitors